MX338247B - Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. - Google Patents

Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Info

Publication number
MX338247B
MX338247B MX2012000083A MX2012000083A MX338247B MX 338247 B MX338247 B MX 338247B MX 2012000083 A MX2012000083 A MX 2012000083A MX 2012000083 A MX2012000083 A MX 2012000083A MX 338247 B MX338247 B MX 338247B
Authority
MX
Mexico
Prior art keywords
storage disease
glycogen
treatment method
disease treatment
polysaccharide storage
Prior art date
Application number
MX2012000083A
Other languages
English (en)
Inventor
Charles Roe
Original Assignee
Baylor Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35787579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338247(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baylor Res Inst filed Critical Baylor Res Inst
Publication of MX338247B publication Critical patent/MX338247B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/174—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Insects & Arthropods (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para tratar enfermedad de almacenamiento de glucógeno al administrar una cantidad efectiva de una composición que incluye ácidos grasos de carbono impar cetogénicos que alivian los síntomas de estas enfermedades.
MX2012000083A 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. MX338247B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58550204P 2004-07-02 2004-07-02
PCT/US2005/023524 WO2006014353A2 (en) 2004-07-02 2005-07-01 Glycogen or polysaccharide storage disease treatment method

Publications (1)

Publication Number Publication Date
MX338247B true MX338247B (es) 2016-04-07

Family

ID=35787579

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012000083A MX338247B (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
MX2007000304A MX2007000304A (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2007000304A MX2007000304A (es) 2004-07-02 2005-07-01 Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.

Country Status (5)

Country Link
US (10) US8106093B2 (es)
EP (2) EP1773317A4 (es)
CA (3) CA2573054C (es)
MX (2) MX338247B (es)
WO (1) WO2006014353A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
CA2573054C (en) 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
US20070203907A1 (en) * 2006-02-03 2007-08-30 Polyglot Systems, Inc. User interface for entry of step changes
NZ575655A (en) * 2006-09-26 2012-06-29 Baylor Res Inst Nutrient sensor
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
CA2704371A1 (en) * 2007-11-01 2009-05-07 Wake Forest University School Of Medicine Compositions and methods for prevention and treatment of mammalian diseases
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
MX2008000951A (es) * 2008-01-21 2008-04-21 Rodolfo Jose Medeles Orozco Suplemento energetico para nutricion animal??.
DE102008057867A1 (de) * 2008-11-18 2010-05-20 B. Braun Melsungen Ag Fettemulsion zur künstlichen Ernährung von schwerkranken Intensivpatienten
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
US20110044964A1 (en) * 2009-08-24 2011-02-24 Hero Nutritionals, LLC Plant-based omega chewable supplement
JP6082596B2 (ja) * 2009-12-30 2017-02-15 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ アルツハイマー病と加齢脳に対する補充療法
US20110301238A1 (en) * 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
CA2801206A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment
US9452135B2 (en) 2012-03-20 2016-09-27 Particle Dynamics International, Llc Gelling agent-based dosage form
WO2014093901A1 (en) 2012-12-13 2014-06-19 Baylor Research Institute At Dallas Triheptanoin for the treatment of glucose transporter 1 deficiency
ES2774321T3 (es) 2013-11-14 2020-07-20 Univ Queensland Trastornos neurodegenerativos y métodos de tratamiento y diagnóstico de los mismos
EP3782610A1 (en) 2013-11-14 2021-02-24 Ultragenyx Pharmaceutical Inc. Solid compositions of triglycerides and uses tehreof
US10328045B2 (en) 2014-09-12 2019-06-25 Children's Medical Center Corporation, Inc. Dietary emulsion formulations and methods for using the same
KR20170100549A (ko) * 2014-12-30 2017-09-04 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 피콜린아미드 화합물
US20220249419A1 (en) * 2016-06-01 2022-08-11 Keto Innovations, Llc C5 ketone compositions, and related methods, for therapeutic and performance supplementation
US20230149329A1 (en) * 2016-06-01 2023-05-18 Keto Innovations, Llc C5 ketone compositions and related methods for therapeutic and performance supplementation
US20180057846A1 (en) 2016-08-30 2018-03-01 KetoneAid Inc. Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy
US20180103655A1 (en) * 2016-10-18 2018-04-19 Ferrara Candy Company Hard Candy with Gummy Center and Systems and Methods for Making Same
US10238618B2 (en) * 2016-12-29 2019-03-26 The United States Of America As Represented By The Secretary Of The Navy Compositions and methods for diagnosis and treatment of anemia
KR20240101693A (ko) * 2017-08-10 2024-07-02 더 칠드런스 메디칼 센터 코포레이션 어유 및/또는 오메가-3 지방산을 포함하는 에멀젼과 관련된 방법 및 조성물
US11760963B2 (en) 2017-08-23 2023-09-19 KetoneAid Inc. Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
IL274701B2 (en) 2017-12-01 2024-07-01 Ultragenyx Pharmaceutical Inc Promote drugs, compositions and methods of their use
US10874131B2 (en) 2017-12-22 2020-12-29 Heliae Development Llc Human and non-human animal use of microbial anaplerotic oil
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020014428A1 (en) 2018-07-11 2020-01-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids
EP3843716A4 (en) * 2018-08-27 2022-06-01 Exerkine Corporation METHODS OF TREATMENT OF LYSOSOMAL STORAGE DISEASES
WO2020146263A1 (en) 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2021195477A1 (en) 2020-03-27 2021-09-30 Ketoneaid, Inc. Ketone ester as a therapeutic treatment of covid-19, long covid, and related viral infections
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
EP4514152A1 (en) * 2022-04-28 2025-03-05 Keto Innovations, LLC C5 ketone compositions, and related methods, for therapeutic and performance supplementation
EP4651868A2 (en) * 2023-01-20 2025-11-26 Keto Innovations, LLC C5 ketones for inducing weight loss and improving cognitive function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3697563A (en) 1970-06-29 1972-10-10 Inst Chemioterapico Italiano S (3,4,5-trimethoxy-benzamido)-alkanoic acids for prophylaxis and treatment of cardiac disorders
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4042684A (en) 1976-03-23 1977-08-16 Annika Britt Kahm Dietetic beverage
US4777045A (en) 1985-07-26 1988-10-11 Nabisco Brands, Inc. High bran snack
US4753963A (en) * 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
CA1302280C (en) 1986-04-21 1992-06-02 Jon Joseph Kabara Topical antimicrobial pharmaceutical compositions and methods
JP2716986B2 (ja) 1987-07-17 1998-02-18 シエーリング アクチエンゲゼルシヤフト ９‐ハロゲン‐（ｚ）‐プロスタグランジン誘導体、その製法及び薬剤としてのその使用
US4871557A (en) 1988-06-15 1989-10-03 Amway Corporation Granola bar with supplemental dietary fiber and method
US4981687A (en) 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5153221A (en) 1990-10-05 1992-10-06 Elena Avram Method for the treatment of acquired immune deficiency syndrome
DE4439947A1 (de) 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE19615035A1 (de) * 1996-04-17 1997-10-23 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Triazinderivaten und Glycerinestern von alpha-Hydroxycarbonsäuren und gesättigten Fettsäuren
US5908631A (en) 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
CA2322641C (en) 1998-03-23 2010-02-16 General Mills, Inc. Encapsulation of components into edible products
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
IL144645A0 (en) * 1999-02-05 2002-05-23 Baylor University Medical Ct Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
CN1245091C (zh) 2000-05-26 2006-03-15 味之素株式会社 家畜饲料
US6746698B2 (en) 2000-07-06 2004-06-08 Grain Processing Corporation Animal feed, method for preparing animal feed, and method for feeding an animal
CA2573054C (en) 2004-07-02 2012-10-09 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
CA2801206A1 (en) * 2010-06-14 2011-12-22 Baylor Research Institute Triheptanoin diet for adult polyglucosan body disease (apbd) treatment

Also Published As

Publication number Publication date
MX2007000304A (es) 2007-06-15
US9186344B2 (en) 2015-11-17
US20060004099A1 (en) 2006-01-05
EP1773317A2 (en) 2007-04-18
US20170239205A1 (en) 2017-08-24
US20130005818A1 (en) 2013-01-03
CA2784420A1 (en) 2006-02-09
CA2573054C (en) 2012-10-09
US20190083442A1 (en) 2019-03-21
US20250082599A1 (en) 2025-03-13
WO2006014353A2 (en) 2006-02-09
CA2784585A1 (en) 2006-02-09
WO2006014353A3 (en) 2006-06-01
EP1773317A4 (en) 2012-10-03
US8106093B2 (en) 2012-01-31
EP3300727A1 (en) 2018-04-04
US20160030375A1 (en) 2016-02-04
US20220395482A1 (en) 2022-12-15
US20140288175A1 (en) 2014-09-25
CA2784420C (en) 2020-11-10
US20210145784A1 (en) 2021-05-20
US20200009102A1 (en) 2020-01-09
CA2573054A1 (en) 2006-02-09
US8697748B2 (en) 2014-04-15

Similar Documents

Publication Publication Date Title
MX338247B (es) Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
WO2007058538A3 (en) Composition with docosapentaenoic acid
SG10201400685SA (en) Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia
WO2006078463A3 (en) Method for treating cardiovascular disease
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
NZ606825A (en) Methods and compositions for treating complement-associated disorders
BRPI0518093A (pt) dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
NZ600167A (en) Concentrated therapeutic phospholipid compositions
UY28860A1 (es) Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos
NZ597031A (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
MY148893A (en) Combination of an hdac inhibitor and an antimetabolite
WO2008012796A3 (en) Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
ATE460940T1 (de) Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen
WO2007147868A3 (en) Prevention of muscle atrophy
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
WO2006002096A3 (en) Low doses of l-citrulline for treating diseases
NO20076657L (no) Kombinasjonsterapi av cancer med AZD2171 og gemcitabin
UY30557A1 (es) Tratamiento y prevencion de la fibrosis intestinal
TW200640467A (en) Compounds and uses thereof
DE602004003173D1 (de) Verwendung von konjugierter Linolsäure zur Behandlung der Erkältung
MXPA05013703A (es) Aivlosin para el tratamiento de una enfermedad causada por brachyspira pilosicoli u ornithobacterium rhinotracheale.
WO2006133231A3 (en) Treatment for neurodegenerative diseases